Acute exacerbation of chronic bronchitis
Conditions
Interventions
Sponsors
Center for Bioequivalence Studies and Clinical Research (CBSCR),International Center for Chemical and Biological Sciences(ICCBS),University of Karachi
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Between the ages of 18-65, both male and female; with BMI 18.5-30kg/m2; 2. Satisfy the diagnostic criteria for acute exacerbation of Simple chronic bronchitis; 3. The main symptom score: expectoration quantification score>=2, cough + expectoration >=6; 4. Course of disease <=7 days; 5. The subject has signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Through examination and verification, the chronic cough is caused by other diseases: pulmonary tuberculosis, pneumonia, pneumoconiosis, bronchial asthma, bronchiectasis, lung abscess, or caused by irritant gases, allergies, and ACE inhibitors; 2. With severe cardiopulmonary dysfunction, cardiopulmonary insufficiency; 3. Patients with severe primary cardiovascular, cerebrovascular, pulmonary, renal, endocrine and hematological diseases, and mental illness; Patients with severe infections: WBC >=11.0 G/L, NEU% >=82%; 4. Subjects with a history if alchol or drug abuse,suspected or confirmed; 5. Body temperature exceed 38.5 degree C before signing consent form; 6. Subjects, who take other antiviral, antibacterial, cough relieving, expectorant and antiasthmatic drugs within 3 days prior to the visit(including beta 2 receptor agonists, anticholinergic agents, theophylline drugs, glucocorticoids, expectorant and Chinese Medicine.); 7. Allergic individuals and those who are known to be allergic to experimental drugs.(Have a clear history of penicillin and cephalosporins allergy.); 8. Pregnant women, lactating women or fertile women who are ready to conceive in 3 months; 9. Subject, who has participated in the past 3 months or is participating in another drug study; 10. The investigator believes that, there is other lesion or condition that reduces possibility of enrollment or makes the enrollment complex, such as changeable work environment, which easily leads to loss of follow-up; 11. Subjects who are not suitable for the clinical trial based on investigators judgment; 12. BMI>30kg/m2.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The improvement of cough before and after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Curative index;Life quality (LCQ score);The onset time of fever reduction and the time of complete fever reduction;Total number of white blood cells and classification count;X-ray examination for the lungs; | — |
Countries
Pakistan
Contacts
Public ContactShang Gao
Hunan Anbang Pharmaceutical Co., Ltd.
Outcome results
None listed